Medexus Pharma, Inc.

Quick facts

Phase 3 pipeline

• APVO101 · Oncology
  APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Medexus Pharma, Inc. portfolio CI brief
• Medexus Pharma, Inc. pipeline updates RSS